• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

General consultation on breakpoints for anaerobic bacteria

EUCAST general and public consultation on breakpoints for anaerobic bacteria. Theconsultation pertains to the clinical breakpoints for Bacteroides spp., Prevotella spp., Fusobacterium necrophorum, Clostridium perfringens and Cutibacterium acnes that have now been reviewed against the MIC and zone…

Get to know more

Fungi (AFST)

Fungi (AFST) The EUCAST AFST develops breakpoints and methods for antimicrobial susceptibility testing of fungi. Clinical breakpoints for fungi are listed in a separate document and are not included into the breakpoint table for bacteria. For MIC distributions for fungi, go to the EUCAST MIC…

Get to know more

Breakpoint tables are used together with other EUCAST guidance

The EUCAST breakpoint tables are part of a system for categorising microorganisms as susceptible (S and I) and resistant (R) to agents approved for use in the treatment of infectious diseases. Breakpoint tables are freely available but we would like to remind users of other parts of the system which…

Get to know more

Aztreonam-avibactam and cefepime-enmetazobactam now available.

Aztreonam-avibactam has now obtained regulatory approval and breakpoints from EMA and EUCAST for Enterobacterales. These are S≤4, R>4 mg/L.Disk diffusion criteria and QC targets and ranges will be published shortly. There are no breakpoints for other species. Cefepime-enmtazobactam has now obtained…

Get to know more

Consultation (14 May - 15 June, extended to 15 July) on revised breakpoints for IV fosfomycin

EUCAST posted a general consultation on revised breakpoints for intravenous fosfomycin. Consultation period 14 May - 15 June, 2022. Revised breakpoints will be published in breakpoint table 2023.

Get to know more

Aminopenicillin breakpoints - guidance on implementing revised breakpoints

Aminopenicillin breakpoints were revised in the breakpoint table 13.0 (2023). EUCAST has been asked to provide guidance on how to implement the revised breakpoints in laboratory practice and systems .

Get to know more

Breakpoints in Brackets

Breakpoints in brackets in EUCAST tables EUCAST breakpoints in brackets Guidance document, 1 December, 2021 Download PDF Recently, EUCAST introduced the concept of “breakpoints in brackets” to warn against the use of specific agents without the use of additional therapeutic measures. For these…

Get to know more

Development of clinical breakpoints and ECOFFs

Development of clinical breakpoints and ECOFFs As with other breakpoints for antimicrobials the background for EUCAST breakpoints are given in Rationale Documents. Since for antifungals specific technical issues in testing may exist, technical notes are developed if needed. As with the general…

Get to know more

Rationale Documents

Rationale Documents Rationale documents pertaining to breakpoints determined by the EUCAST Veterinary Subcommittee. Florfenicol (Cattle) Rationale for EUCAST clinical breakpoints, version 1.0 10 August 2019 Download PDF Amoxicillin-Clavulanic Acid (AMC) Dog: oral and iv administration (VetCAST)…

Get to know more

Proposed revision of breakpoints for trimethoprim-sulfamethoxazole and trimethoprim.

Proposed revision of breakpoints for trimethoprim-sulfamethoxazole and trimethoprim - public consultation 2025-05-07 - 2025-06-18. The current breakpoints of trimethoprim-sulfamethoxazole are higher than the epidemiological cut-off values for several species. There is absence of PK/PD data for…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here